International Journal of Clinical Research
International Journal of Clinical Research. 2025; 9: (8) ; 10.12208/j.ijcr.20250381 .
总浏览量: 59
皖南医学院第一附属医院（弋矶山医院） 安徽芜湖
*通讯作者： 汪程慧,单位：皖南医学院第一附属医院（弋矶山医院） 安徽芜湖；
特鲁索综合征（Trousseau syndrome）是一种与恶性肿瘤相关的血栓栓塞并发症，以反复血栓事件（如深静脉血栓和脑梗死）为特征。特鲁索综合征的发生频率在不同癌症类型中存在显著差异。其发病机制复杂，涉及肿瘤相关血栓形成、炎症反应及凝血功能异常。诊断依赖于临床表现、影像学检查（如CT、MRI）和实验室检查（如D-二聚体）。治疗主要包括抗凝治疗、肿瘤治疗及综合管理。特鲁索综合征的出现常提示肿瘤晚期，预后较差。患者的预后与肿瘤类型、分期、年龄及基础疾病密切相关。未来需进一步探索其流行病学、病理生理机制及优化治疗策略，以改善患者预后和生活质量。
Trousseau syndrome is a thromboembolic complication associated with malignant tumors, characterized by recurrent thrombotic events (such as deep vein thrombosis and cerebral infarction). The incidence of Trousseau syndrome varies significantly among different types of cancers. Its pathogenesis is complex, involving tumor-related thrombosis, inflammatory response, and abnormal coagulation function. Diagnosis depends on clinical manifestations, imaging examinations (such as CT, MRI), and laboratory tests (such as D-dimer). Treatment mainly includes anticoagulant therapy, tumor treatment, and comprehensive management. The occurrence of Trousseau syndrome often indicates advanced-stage tumors and a poor prognosis. The prognosis of patients is closely related to the type of tumor, stage, age, and underlying diseases. In the future, it is necessary to further explore its epidemiology, pathophysiological mechanisms, and optimize treatment strategies to improve the prognosis and quality of life of patients.
[1] Bao L, Zhang S, Gong X, et al. Trousseau Syndrome Related Cerebral Infarction: Clinical Manifestations, Laboratory Findings and Radiological Features[J]. Journal of Stroke and Cerebrovascular Diseases: The Official Journal of National Stroke Association, 2020, 29(9): 104891.
[2] Aoyama K I, Tamura M, Uchibori M, et al. Trousseau syndrome in a patient with advanced oral squamous cell carcinoma: a case report[J]. Journal of Medical Case Reports, 2019, 13(1): 26.
[3] Ikeda H, Enatsu R, Yamana N, et al. Multiple extra-ischemic hemorrhages following intravenous thrombolysis in a patient with Trousseau syndrome: case study[J]. SpringerPlus, 2015, 4: 141.
[4] Kuwahata S, Takenaka T, Yasuda S, et al. A case of anticoagulant treatment-resistant Trousseau syndrome controlled by treatment of the underlying lung adenocarcinoma: Utility of monitoring D-dimer levels[J]. Journal of Cardiology Cases, 2017, 15(2): 65-69.
[5] Nonagase Y, Takeda M, Tanaka K, et al. Treatment of EGFR mutation-positive non-small cell lung cancer complicated by Trousseau syndrome with gefitinib followed by osimertinib: a case report[J]. Oncotarget, 2018, 9(50): 29532-29535.
[6] Shapoo N, Boma N, Chaudhari S, et al. Solid Tumors, Liquid Challenges: The Impact of Coagulation Disorders[J]. Hematology Reports, 2025, 17(1): 8.
[7] Hsieh K Y, Tsai J Y, Lin Y H, et al. Golden berry 4β-hydroxywithanolide E prevents tumor necrosis factor α-induced procoagulant activity with enhanced cytotoxicity against human lung cancer cells[J]. Scientific Reports, 2021, 11(1): 4610.
[8] Callander N S, Varki N, Rao L V. Immunohistochemical identification of tissue factor in solid tumors[J]. Cancer, 1992, 70(5): 1194-1201.